European News. Novo will present its advances in hematology [CercleFinance]
$Novo-Nordisk A/S (NVO.US)$ announces the presentation of 13 abstracts, during the 66th Annual Meeting of the American Society of Hematology (ASH) which will take place will be held in San Diego December 7-10, 2024. Presentations include 52-week results from the phase HIBISCUS trial 2/3 on etavopivat will be presented on December 7, highlighting its effectiveness and safety for the treatment of sickle cell disease.
Additionally, two oral presentations concern the FRONTIER4 and explorer7 studies on Mim8 and concizumab, respectively, for the treatment of sickle cell disease. hemophilia A with and without inhibitors. Martin Holst Lange, executive vice president of Novo Nordisk, highlighted the importance of this research in meeting the needs dissatisfied patients with rare blood diseases.
Conclusion; Blood diseases are an important issue in the future modern world![]()
![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
